Key facts
- It has raised $10.1M across 4 recorded rounds; the latest was Seed Round ($500K) in Jan 2026.
- Notable investors include US National Science Foundation, National Center For Advancing Translational Sciences, U.S. Department of Health and Human Services.
- Spheryx has filed 5 Form Ds with the SEC since 2015, most recently Apr 2023 ($675K sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Spheryx
Funding rounds
4 roundsAbout Spheryx
Developer of a suspension analysis technology designed for quality control and formulation development across multiple industry segments. The company's technology is based on holographic video microscopy to characterize particles suspended in fluids in complex heterogeneous mixtures of colloidal microspheres, emulsion droplets, or nanoparticles, enabling the clients to gain predictive knowledge of their particulate suspension behavior for formulation optimization, quality assurance screening, manufacturing process control, and sample analysis.
- Sector
- Information Technology
- HQ
- New York, NY, United States
- Founded
- 2014
- Employees
- 14
- Website
- spheryx.solutions/
- Ownership
- Privately Held (backing)
Spheryx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Spheryx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Spheryx in its N-PORT filings yet. We sweep new filings monthly.